ESTRO 2024 - Abstract Book

S5103

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2024

3. Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersall P, et al. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol. 2021;16(7):1200-10. Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindback E, Jirf KA, et al. Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors. Int J Radiat Oncol Biol Phys. 2023. 4.

2158

Digital Poster

A Survival-Driven Radiotherapy Plan Quality Index for Nasopharyngeal Cancer: A Multicenter Study

Jiang Zhang 1 , Xinzhi Teng 1 , Saikit Lam 2 , Zongrui Ma 1 , Xinyang Han 1 , Xinyu Zhang 1 , Andy Lai-Yin Cheung 3 , Tin-Ching Chau 4 , Francis Kar-Ho Lee 5 , Kwok-Hung Au 5 , Celia Wai-Yi Yip 5 , Victor Ho-Fun Lee 6 , Jing Cai 1 1 The Hong Kong Polytechnic University, Department of Health Technology and Informatics, Hong Kong, Hong Kong. 2 The Hong Kong Polytechnic University, Department of Biomedical Engineering, Hong Kong, Hong Kong. 3 St. Paul's Hospital, Department of Clinical Oncology, Hong Kong, Hong Kong. 4 Queen Marry Hospital, Department of Clinical Oncology, Hong Kong, Hong Kong. 5 Queen Elizabeth Hospital, Department of Clinical Oncology, Hong Kong, Hong Kong. 6 The University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong

Purpose/Objective:

Presently, patient survival has not been considered for radiotherapy (RT) plan assessment. Incorporating prognostication into RT plan assessment would potentially provide actionable insights for oncologists and physicists into plan optimization at the point of care, presenting a novel game-changing idea. Therefore, we aimed to develop a tumor-derived dosiomics index (TDDI) to assess prognostic power of RT plan for nasopharyngeal carcinoma (NPC) patients in a multi-institutional setting.

Material/Methods:

A total of 234 and 140 biopsy-proven NPC patients were retrospectively collected from two local hospitals and assigned to a training and an external validation cohort, respectively. Dosiomics features, extracted from both primary (GTVp) and nodule (GTVn) gross-tumor-volume, were selected according to their inter-feature redundancy and clinical relevance, and were utilized to develop a TDDI in the training cohort by using multivariate Cox regression for disease-free survival (DFS) overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS). The median value of the TDDI was subsequently employed to stratify RT plans into a high-quality plan group and a low-quality plan group. Corrected hazard ratio (HR) from multivariate Cox regression were used to evaluate performance of the TDDI in both training and external validation cohorts.